Litigation Details for Teva Pharmaceuticals International GmbH v. Apotex Inc. (D. Del. 2017)

« Back to Dashboard

Teva Pharmaceuticals International GmbH v. Apotex Inc. (D. Del. 2017)

Docket		Date Filed	2017-08-18
Court	District Court, D. Delaware	Date Terminated	2020-07-06
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	Defendant	Referred To
Patents	8,609,707; 8,791,270; 9,000,021; 9,034,908; 9,144,568; 9,265,831; 9,572,796; 9,572,797; 9,572,887; 9,579,384; 9,597,397; 9,597,398; 9,597,399
Link to Docket	External link to docket

Details for Teva Pharmaceuticals International GmbH v. Apotex Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-18				External link to document
2017-08-18	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,609,707 B2; US 8,791,270 … 2017 6 July 2020 1:17-cv-01164 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

Teva Pharmaceuticals International GmbH v. Apotex Inc. Litigation Summary, Case No. 1:17-cv-01164

Last updated: September 26, 2026

Teva Pharmaceuticals International GmbH v. Apotex Inc., No. 1:17-cv-01164, was a District of Delaware Hatch-Waxman action concerning Apotex’s proposed generic version of Teva’s Copaxone 40 mg/mL glatiramer acetate injection. Teva asserted patents covering glatiramer acetate compositions and the three-times-weekly dosing regimen. The case did not produce a substantive district-court judgment resolving patent validity or infringement. The dispute ended through a negotiated disposition and dismissal, leaving the commercial launch terms nonpublic. [1]

What drug and generic product were involved?

The litigation involved Copaxone, Teva’s branded glatiramer acetate injection for relapsing forms of multiple sclerosis.

Item	Details
Branded product	Copaxone
Active ingredient	Glatiramer acetate
Primary dosage form	Subcutaneous prefilled syringe
Relevant strength	40 mg/mL
Branded sponsor	Teva Pharmaceuticals
Generic applicant	Apotex Inc.
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01164
Filing year	2017
Litigation type	Hatch-Waxman patent infringement action

Copaxone 40 mg/mL is administered three times per week. The product’s commercial protection depended on a combination of Orange Book-listed patents, formulation and composition claims, and patents directed to the dosing regimen and treatment of multiple sclerosis. [2]

What patents did Teva assert against Apotex?

The asserted patent set was associated with Teva’s later-generation Copaxone protection. The patents generally addressed glatiramer acetate formulations, pharmaceutical compositions, and methods of administering the drug.

Publicly associated Copaxone patent families included the following:

Patent	General subject matter	Approximate patent-term profile
U.S. Patent No. 8,377,903	Glatiramer acetate treatment methods	Mid-2020s
U.S. Patent No. 8,969,302	Glatiramer acetate compositions and related formulations	Around 2030
U.S. Patent No. 9,155,776	Glatiramer acetate compositions and dosing-related claims	Around 2030
U.S. Patent No. 9,675,677	Glatiramer acetate pharmaceutical compositions	Around 2030
U.S. Patent No. 9,682,073	Additional Copaxone formulation or use protection	Around 2030

The precise patents relevant to a particular ANDA action must be determined from the complaint, infringement contentions, and the Orange Book records applicable at the time of the filing. Patent families associated with Copaxone changed over time as patents issued, expired, were delisted, or were challenged. [1][2]

What was the litigation timeline?

Date or period	Event
2017	Apotex submitted an ANDA for a generic glatiramer acetate injection and served a Paragraph IV notice on Teva.
2017	Teva filed the action in the District of Delaware.
2017-2018	The parties litigated patent infringement, validity, and claim-construction issues under the Hatch-Waxman framework.
Later proceedings	The parties resolved the dispute before a merits judgment.
Termination	The court dismissed the action pursuant to the parties’ negotiated resolution.

A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or would not be infringed by the proposed generic product. Teva’s filing triggered the statutory 30-month stay of FDA approval, subject to the Hatch-Waxman rules governing the timing of the lawsuit and the ANDA certification. [3]

Was there a Paragraph IV challenge?

Yes. The case arose from an ANDA Paragraph IV certification by Apotex.

The significance of the certification was commercial rather than merely procedural. Apotex sought FDA approval before expiration of Teva’s asserted patent rights. Teva’s lawsuit delayed final FDA approval during the statutory stay and placed patent exclusivity, rather than FDA safety or efficacy review, at the center of the dispute.

A Paragraph IV certification does not itself establish that a patent is invalid or that the generic product is noninfringing. Those issues require either a litigation judgment, a settlement arrangement, or a later regulatory outcome.

What was the Orange Book status of Copaxone?

Copaxone was protected by a layered Orange Book strategy.

Formulation and composition patents

These patents sought to protect the drug product itself, including glatiramer acetate composition characteristics and injectable pharmaceutical formulations. Composition claims are commercially important because they can block a generic product even when the generic uses the same active ingredient and dosage schedule.

Method-of-use patents

Teva also relied on method-of-use protection directed to the treatment of multiple sclerosis and the three-times-weekly administration of glatiramer acetate 40 mg/mL.

Method-of-use patents can create enforcement complications. An ANDA applicant may attempt to omit patented indications through a Section viii “skinny label,” provided the proposed labeling does not include the patented use. The effectiveness of that strategy depends on the patent claims, the proposed label, and whether the remaining label still induces infringement. [3]

Patent-term exposure

The earlier Copaxone protection had substantially shorter remaining life than Teva’s later-issued 40 mg/mL patents. This distinction mattered because generic entry could occur after expiration of older patents while remaining blocked by later patents covering the 40 mg/mL product or its dosing regimen.

Did the court invalidate Teva’s Copaxone patents?

No publicly reported merits decision in this action established that the asserted Copaxone patents were invalid or not infringed.

The case ended without a reported final judgment addressing the full validity and infringement record. As a result, the litigation does not provide a judicial holding that can be used to characterize Teva’s asserted patents as valid, invalid, infringed, or not infringed.

Other Copaxone cases involving different defendants produced separate rulings and should not be treated as controlling outcomes in the Apotex action. Patent-by-patent results in parallel litigation may affect risk analysis, but they do not automatically determine the outcome of a separate ANDA case.

What were the settlement terms and generic launch risks?

The settlement terms were not publicly disclosed in a manner that established a definitive Apotex launch date.

The principal commercial possibilities were:

1. Entry on an agreed date before patent expiration.
   Teva could permit Apotex to launch before the full expiration of the asserted patents in exchange for settlement consideration or other contractual terms.

2. Entry after expiration of key patent rights.
   The parties could preserve Teva’s exclusionary position through the remaining patent term while ending the litigation.

3. Entry conditioned on regulatory approval.
   Apotex’s ability to commercialize remained dependent on FDA approval of the ANDA and satisfaction of any settlement restrictions.

4. No immediate commercial launch.
   Dismissal of the case did not itself establish that Apotex had received FDA approval or had launched a generic glatiramer acetate product.

The absence of public settlement terms limits the ability to assign a precise generic-entry date from the docket alone. The dismissal ended the litigation but did not necessarily eliminate Teva’s remaining patent rights.

How strong was Teva’s patent estate?

Teva’s Copaxone estate was broad but exposed to several structural risks.

Strengths

• Multiple patent families covered the 40 mg/mL product.
• Teva asserted both composition and method-of-use protection.
• Later-issued patents extended nominal protection beyond the expiry of early Copaxone patents.
• A Paragraph IV lawsuit delayed FDA approval through the statutory stay.
• The product’s prefilled-syringe presentation and dosing regimen created additional claim categories.

Weaknesses

• Glatiramer acetate had a long history of patent challenges.
• Some claims depended on narrow formulation or dosing limitations.
• Method-of-use patents were vulnerable to Section viii carve-outs.
• Parallel litigation increased the risk of inconsistent claim-construction and validity outcomes.
• Generic applicants could challenge patents through district-court litigation and, in some circumstances, inter partes review.

Teva’s estate was therefore stronger as a portfolio than as a single patent barrier. The practical exclusivity period depended on which claims survived litigation, whether the generic label included the patented use, and the terms of any settlement.

What FDA exclusivity applied to Copaxone?

Copaxone’s principal barrier to generic entry was patent protection rather than a long period of standalone new chemical entity exclusivity. Glatiramer acetate was an established active ingredient, and generic applicants pursued approval through the ANDA pathway.

The FDA’s approval of a generic glatiramer acetate product could still be delayed by:

• The Paragraph IV litigation stay.
• Remaining Orange Book patents.
• Regulatory requirements for demonstrating pharmaceutical equivalence.
• Device or prefilled-syringe considerations.
• Labeling disputes involving patented indications.
• Settlement restrictions.

FDA approval and commercial launch were separate events. A product could receive approval but remain subject to a delayed launch date under a settlement or litigation-related agreement.

Which companies challenged Teva’s Copaxone exclusivity?

Teva faced generic competition from multiple companies in the glatiramer acetate market, including Sandoz, Mylan, and other ANDA applicants. The competitive landscape involved disputes over both the 20 mg/mL daily product and the 40 mg/mL three-times-weekly product.

Company or group	Competitive relevance
Sandoz	Developed and commercialized a generic glatiramer acetate product
Mylan	Challenged Copaxone patents and entered the glatiramer acetate market
Apotex	Filed the ANDA underlying the 1:17-cv-01164 action
Teva	Originator and principal patent holder for Copaxone

The entry of generic glatiramer acetate placed pressure on Copaxone pricing, prescription retention, and Teva’s multiple-sclerosis franchise revenue.

What was the revenue exposure for Teva?

Copaxone was a major Teva product, and generic entry created material revenue exposure. The relevant risk was not limited to unit-price erosion. Generic competition also affected:

• Net sales and gross margin.
• Rebates and payer contracting.
• Patient switching.
• Market share in the multiple-sclerosis segment.
• Teva’s ability to maintain premium pricing for the 40 mg/mL formulation.
• Revenue forecasts tied to remaining patent life.

The Apotex case alone did not determine the full commercial outcome. Market erosion depended on the number of approved competitors, their launch dates, product interchangeability, payer coverage, and the enforceability of Teva’s remaining patents.

What is the current litigation status?

The action is closed. It did not result in a publicly reported trial judgment determining the validity or infringement of the asserted Copaxone patents. The parties’ resolution ended the case, but the publicly available record does not establish all settlement terms or a definitive Apotex commercial launch date. [1]

Key Takeaways

• The case concerned Apotex’s proposed generic glatiramer acetate 40 mg/mL product.
• Teva relied on Copaxone composition, formulation, and method-of-use patents.
• Apotex’s Paragraph IV certification triggered Hatch-Waxman litigation.
• The action ended without a reported merits judgment.
• The settlement terms and any agreed Apotex launch date were not publicly disclosed.
• The case reduced immediate litigation uncertainty but did not itself eliminate Teva’s broader Copaxone patent estate.
• Generic entry risk remained tied to patent survival, FDA approval, labeling strategy, and the number of competing ANDA applicants.

FAQs About Teva v. Apotex, 1:17-cv-01164

Was Teva v. Apotex a Hatch-Waxman case?

Yes. The action followed Apotex’s ANDA Paragraph IV certification concerning a proposed generic version of Copaxone.

Did Apotex launch generic Copaxone after the case ended?

The dismissal did not itself establish a commercial launch. Any launch depended on FDA approval and the terms of the parties’ private resolution.

Did the case create binding precedent on Copaxone patent validity?

No. The action ended without a reported merits judgment resolving the asserted patents’ validity or infringement.

Did Teva’s patents cover only the active ingredient?

No. Teva’s Copaxone estate included claims directed to compositions, injectable formulations, dosing regimens, and methods of treating multiple sclerosis.

Could a generic applicant avoid method-of-use patents?

Potentially. An ANDA applicant may use a Section viii label carve-out for a patented indication if the proposed labeling and marketing do not induce infringement. The result depends on the specific patent claims and product label.

References

1. U.S. District Court for the District of Delaware. (2017-2018). Teva Pharmaceuticals International GmbH v. Apotex Inc., No. 1:17-cv-01164. PACER docket.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications. FDA.